跳至主要内容
临床试验/NCT03383887
NCT03383887已完成1 期

Effect of DAW1033D on Obstructive Sleep Apnea and Its Phenotypic Traits

Brigham and Women's Hospital1 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2017年12月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
11
试验地点
1
主要终点
Apnea Hypopnea Index (AHI, Events/Hour of Sleep)

研究概览

简要总结

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of DAW1033D administered before sleep on OSA phenotype traits and OSA severity during sleep.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • AHI > 15

排除标准

  • Any medical condition other than well controlled hypertension, diabetes, hyperlipidemia
  • Any medication known to influence breathing, sleep/arousal or muscle physiology.
  • Claustrophobia.
  • Inability to sleep supine.
  • Allergy to lidocaine, Oxymetazoline HCl, DAW1033D.
  • Individuals with underlying cardiac disease, such as arrhythmias.
  • Individuals taking psychiatric medications, or any of the studied medications for medical care.
  • History of seizures
  • For women: Pregnancy.
  • History of panic disorder / hyperventilation syndrome / Attention deficit-hyperactivity disorder (ADHD) / autism

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo capsule 30 minutes before sleep

干预措施: Placebo oral capsule (Drug)

DAW1033D

Active Comparator

DAW1033D capsule 30 minutes before sleep

干预措施: DAW1033D oral capsule (Drug)

结局指标

主要结局

Apnea Hypopnea Index (AHI, Events/Hour of Sleep)

时间窗: 1 night

Based on previous studies the investigators anticipate that DAW1033D will reduce AHI more effectively in subjects with moderate sleep apnea, and mild to moderate pharyngeal collapsibility. AHI describes the frequency of obstruction of the upper airway during sleep and is commonly used to describe the presence and severity of obstructive sleep apnea.

次要结局

  • Collapsibility of the Upper Airway: VPassive(1 night)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

David Andrew Wellman

Associate professor HMS

Brigham and Women's Hospital

研究点 (1)

Loading locations...

相似试验